6RC
vs
D
DAX Index
6RC
Over the past 12 months, 6RC has underperformed DAX Index, delivering a return of -27% compared to the DAX Index's +11% growth.
Stocks Performance
6RC vs DAX Index
Performance Gap
6RC vs DAX Index
Performance By Year
6RC vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ReproCell Inc
Glance View
ReproCELL Inc. engages in stem cell research. The company is headquartered in Yokohama, Kanagawa-Ken and currently employs 106 full-time employees. The company went IPO on 2013-06-26. The firm operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.